An early phase II study of FK 037 for respiratory tract infections

Rinzo Soejima, Yoshihito Niki, Niro Okimoto, Osamu Moriya, Masaru Sumi, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Akira Watanabe, Yutaka Tokue, Shigeo Takizawa, Mikae Nakamura, Kohya Shiba, Osamu Sakai, Atsushi Saito, Kaoru Shimada, Takashi Inamatsu, Hiroyuki Kobayashi, Seiji Hori, Jingoro ShimadaFumio Matsumoto, Takeo Imai, Kouji Yoshikawa, Fumio Miki, Toshiharu Matsushima, Makoto Kimura, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Sadahiro Asai, Naofumi Suyama, Jun Araki, Hideo Mashimoto, Rokushi Oka, Tatsuya Katsumata, Keizo Matsumoto, Hiroshi Watanabe, Akemi Ohmori, Moritoshi Akiyama, Yoshiaki Utsunomiya, Kazunori Ooishi, Tsuyoshi Nagatake, Atsushi Saito, Jun Inatome, Hiroshi Fukuhara

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

An early phase II trial of FK 037, a parenteral cephalosporin, was conducted in patients with respiratory tract infections. 1) The efficacy, safety and usefulness of FK 037 were evaluated in 41 patients with respiratory tract infections who were intravenously infused with the drug at a dose of 0.5, 1.0 or 2.0 g, twice daily, for 3 to 14 days, as a rule. 2) Efficacy in 39 patients who were evaluable (26 with pneumonia, 8 with chronic respiratory tract infections, 3 with pyothorax or pleurisy, and 2 with acute bronchitis), was “excellent” in 15 and “good” in 19, an efficacy rate of 87.2%. The efficacy rates by dosage were 91.7% (11/12), 100% (19/19) and 66%(4/6) at 0.5 g b. i. d., 1.0 g b. i. d. and 2.0 g b. i. d., respectively. 3) All of 9 strains of Streptococcus pneumoniae, 7 strains of Haemophilus influenzae and 2 strains of Pseudomonas aeruginosa were eradicated by FK 037 dosing. Of 27 bacterial strains detected, 25 strains (92.6%) were eradicated. 4) No side effects were seen. Abnormal changes in laboratory tests were noted in 12 (30.0%) out of 40 patients who were evaluated for safety. These were mostly mild increases in hepatic enzyme levels, and there were no cases associated with clinical signs or serious cases. 5) The drug was rated “remarkably useful” in 10, of 38 evaluable patients, “useful” in 23, “slightly useful” in 2 and “not useful” in 3, a usefulness rate of 86.8%. These results suggest that FK 037 can be given with good results at clinical doses of 0.5 g b. i. d., 1.0 g b. i. d. and 2.0 g b. i. d.

Original languageEnglish
Pages (from-to)1128-1142
Number of pages15
JournalChemotherapy
Volume42
Issue number10
DOIs
Publication statusPublished - 1994

Keywords

  • FK 037
  • clinical study
  • early phase II trial
  • infections in internal medicine
  • respiratory tract infections

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Fingerprint Dive into the research topics of 'An early phase II study of FK 037 for respiratory tract infections'. Together they form a unique fingerprint.

Cite this